| 张越虹 庄军 桑莉 滕菲 魏玉复.辛伐他汀联合低分子肝素对慢性心衰心肺功能及相关指标的影响[J].,2016,16(2):299-301 |
| 辛伐他汀联合低分子肝素对慢性心衰心肺功能及相关指标的影响 |
| Influence of Simvastatin plus Low Molecular Heparin on CardiopulmonaryFunction and Relevant Indexes in Chronic Heart Failure |
| |
| DOI： |
| 中文关键词: 辛伐他汀 低分子肝素 慢性心衰 |
| 英文关键词: Simvastatin Low molecular heparin Chronic heart failure |
| 基金项目: |
|
| 摘要点击次数: 1033 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探索辛伐他汀联合低分子肝素对慢性心力衰竭（CHF）患者的D- 二聚体、N- 末端脑钠肽前体（NT-proBNP）、左室射血
分数（LVEF）、左室舒末内径、血清反应蛋白（CRP）、血浆纤维蛋白原（FB）、血清总胆固醇（TC）及低密度脂蛋白胆固醇（LDL-C）的
影响。方法：选择我院自2010 年4 月至2014 年7 月间收治的患有CHF患者80 例，按照随机数表法分成治疗组和对照组，各40
例。两组均给予常规治疗，治疗组在常规治疗的基础上加用辛伐他汀和低分子肝素，治疗两个月。对比两组患者治疗前后D- 二聚
体、NT-proBNP、LVEF、左室舒末内径、CRP、FB、TC 和LDL-C 水平。结果：与治疗前相比，对照组患者治疗后的D- 二聚体、
NT-proBNP、LVEF、左室舒末内径、CRP、FB、TC和LDL-C水平均无明显改善，而治疗组患者上述各项指标均显著改善，差异均具
有统计学意义（均P<0.05）。结论：临床上应用辛伐他汀联合低分子肝素可以有效改善CHF 患者的相关指标，对于疾病的治疗具
有重要作用，值得在临床上应用及推广。 |
| 英文摘要: |
| Objective:To explore the influence of simvastatin plus low molecular heparin on D-dimer, N-terminal brain natriuretic
peptide precursor(NT-proBNP), left ventricular ejection fraction(LVEF), left ventricular end-diastolic diameter, serum c-reactive protein
(CRP), plasma fibrinogen (FB), serumtotal cholesterol (TC), low density lipoprotein cholesterol (LDL-C) in patients with chronic heart
failure (CHF).Methods:A total of 80 patients with CHF, who were treated in Dalian Center Hospital fromApril 2010 to July 2014 ,were
selected and randomly divided into treatment group (n=40) and control group (n=40). The two groups were all treated with conventional
therapy, based on which, the treatment group was added simvastatin plus low molecular heparin, the course of treatment was two months.
The levels of D-dimer, NT-proBNP, LVEF, left ventricular end-diastolic diameter, CRP, FB, TC and LDL-C in the two groups before and
after treatment were compared.Results:Compared with before treatment, the levels of D-dimer, NT-proBNP, LVEF, left ventricular
end-diastolic diameter, CRP, FB, TC and LDL-C in the control group after treatment were not obviously improved, while the above
indexes in the treatment group were improved significantly, the differences were statistically significant(P<0.05).Conclusion:Simvastatin
plus low molecular heparin can effectively improve the relevant indexe of patients with CHF, which plays an important role in the clinical
treatment and is worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
